title: Transplantation of CD34+ selected peripheral blood to HLA-identical sibling patients with aplastic anaemia: results from a single institution.
abstract: We evaluated the use of CD34+ selected allogeneic peripheral blood as a source of hematopoietic progenitors for allogeneic transplantation in 11 patients with aplastic anemia (AA). The median age was 17 years (range, 6--9), and the median time between diagnosis and transplant 1 month (range, 1--4). Conditioning consisted of cyclophosphamide (50 mg/kg per day) on days--7 to--4 and antithymocyte globulin (30 mg/kg per day) on days--4 to--2 in nine patients. Total lymphoid irradiation was added to the preparative regimen for two. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine A and prednisone. Median doses of CD34+ and CD3+ cells infused were 3.91 x 10(6) and 0.3 x 10(6)/kg, respectively. The median time taken to achieve a neutrophil count >0.5 x 10(9)/l was 12 days and to recover a platelet count >20 x 10(9)/l, 13 days. Two patients developed acute GVHD grade I--II and one developed limited chronic GVHD. There were two treatment-related deaths. At a median follow-up of 44 months (range, 4--3), nine patients were alive with sustained and complete engraftment. This is a promising procedure in patients with AA, resulting in a rapid hematopoietic recovery, a low transplant-related mortality, and a low incidence of GVHD.
authors.affiliation: Bone Marrow Transplant Unit, Hematology Service, University Hospital La Fe, Valencia, Spain.
authors.forename: J
authors.initials: J
authors.lastname: de la Rubia
authors.forename: S
authors.initials: S
authors.lastname: Cantero
authors.forename: G F
authors.initials: GF
authors.lastname: Sanz
authors.forename: M J
authors.initials: MJ
authors.lastname: Remigia
authors.forename: E
authors.initials: E
authors.lastname: Monteagudo
authors.forename: F
authors.initials: F
authors.lastname: Moscardó
authors.forename: G
authors.initials: G
authors.lastname: Martín
authors.forename: I
authors.initials: I
authors.lastname: Lorenzo
authors.forename: C
authors.initials: C
authors.lastname: Jiménez
authors.forename: J
authors.initials: J
authors.lastname: Martínez
authors.forename: P
authors.initials: P
authors.lastname: Montesinos
authors.forename: I
authors.initials: I
authors.lastname: Jarque
authors.forename: M A
authors.initials: MA
authors.lastname: Sanz
mesh_terms: D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000150:complications / Q000401:mortality / Q000628:therapy*; D018952:Antigens, CD34; D017252:CD3 Complex; D002648:Child; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D007700:Kinetics; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D011292:Premedication; D018714:Radiotherapy, Adjuvant; D035781:Siblings; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D017252:CD3 Complex